uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The safety of rosuvastatin in comparison with other statins in over 25 000 statin users in the Saskatchewan Health Databases
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology.
Show others and affiliations
2008 (English)In: Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, E-ISSN 1099-1557, Vol. 17, no 10, 953-961 p.Article in journal (Refereed) Published
Abstract [en]

Purpose To compare mortality and the incidence of hospitalization for myopathy, rhabdomyolysis, acute renal failure and acute liver injury in patients receiving rosuvastatin and those taking other statins. Methods Patients prescribed a statin that they had not used before were selected from the Saskatchewan Health Databases (SHD) and followed up from 1 July 2003 until 31 March 2005. Results We studied 10 384 patients on rosuvastatin and 14 854 taking other statins. Two cases of myopathy were identified (one on rosuvastatin, one on another statin). The relative risk (RR) of myopathy in patients currently taking rosuvastatin compared with other statins was 1.31 (95% confidence interval [CI]: 0.13-13.41). Two cases of rhabdomyolysis were detected among current rosuvastatin users (incidence: 2.9 [95% CI: 0.8-10.71 per 10 000 person-years). No cases of acute liver injury occurred among rosuvastatin patients. Seventeen cases of acute renal failure were identified (five among rosuvastatin users, 12 taking other statins). The RR of acute renal failure in current rosuvastatin users compared with other statins was 0.49 (95% CI: 0.16-1.50). We identified 285 deaths during the study period (87 among rosuvastatin users, 198 taking other statins). The RR of death in current rosuvastatin users compared with other statins was 0.42 (95% CI: 0.32-0.57). Conclusions We found no evidence that patients prescribed rosuvastatin were at greater risk of the study outcomes than patients prescribed other statins. There was no evidence of increased mortality among patients taking rosuvastatin, even after allowing for age, sex and prior statin use.

Place, publisher, year, edition, pages
2008. Vol. 17, no 10, 953-961 p.
Keyword [en]
pharmacoepidemiology, rosuvastatin, statin, safety
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-107829DOI: 10.1002/pds.1602ISI: 000260094000002OAI: oai:DiVA.org:uu-107829DiVA: diva2:233279
Available from: 2009-08-31 Created: 2009-08-31 Last updated: 2011-08-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Wallander, Mari-Ann
By organisation
Family Medicine and Clinical Epidemiology
In the same journal
Pharmacoepidemiology and Drug Safety
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 193 hits
ReferencesLink to record
Permanent link

Direct link